Monitor the initiation of the Phase 2 alopecia areata study by year-end 2026 and any updates on the ADAPTIVE trial enrollment. The reduced cash burn extends the runway, but the company remains pre-revenue with no near-term catalyst until ADAPTIVE topline data in Q4 2027.
Drug in focus
IMA drug pipeline →olevaprubart
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2b
- Time to market
- If the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $3.81entry
- T+1 · 6d ago −2.36%α −3.68% · $3.72
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImageneBio reported Q3 2026 net loss of $15.6M ($0.91 per share), narrower than the $24.8M loss ($2.91 per share) in Q3 2025, driven by lower R&D and G&A expenses. The Phase 2b ADAPTIVE trial in atopic dermatitis continues as planned with topline data expected in Q4 2027, and a Phase 2 alopecia areata study is on track to start by year-end 2026. Cash of $126.6M provides runway into Q1 2028.
Key Financial Metrics
Key Facts
- Net loss of $15.6M for Q3 2026 vs $24.8M for Q3 2025
- Net loss per share $0.91 vs $2.91 in prior year period
- Cash, cash equivalents and marketable securities of $126.6M as of Sep 30, 2026
- R&D expenses $11.3M vs $15.2M in Q3 2025
- G&A expenses $6.0M vs $11.0M in Q3 2025
- Phase 2b ADAPTIVE trial topline data expected Q4 2027
- Phase 2 alopecia areata study on track to initiate by end of 2026
- No cases of Kaposi sarcoma observed across all clinical trials to date
Financial Impact
Net loss improved by $9.2M year-over-year; cash burn rate appears reduced with lower operating expenses
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products or revenue stream
- Single pipeline asset (olevaprubart/IMG-007) concentration risk
- ADAPTIVE trial topline data not expected until Q4 2027, over a year away
- Potential need for additional capital before reaching key data milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453639 |
| Document: d139863d8k.htm | 0001193125-26-453639 |
| Document: 0001193125-26-453639-index-headers.html | 0001193125-26-453639 |
| Document: 0001193125-26-453639-index.html | 0001193125-26-453639 |
| Document: 0001193125-26-453639.txt | 0001193125-26-453639 |
| 8-K Data (Synthetic) | 0001193125-26-453639 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers